The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26)
Official Title: Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26)
Study ID: NCT05112549
Brief Summary: To determine the safety of intrathecal (IT) PD1 antibody for Intrathecal application of PD1 antibody in metastatic solid tumors with leptomeningeal disease of solid tumors.
Detailed Description: Leptmeningeal disease (LMD) is an aggressive subtype of metastatic disease in the central nervous system (CNS) and has a poor prognosis with a median overall survival of a few months.The IT-PD1 trial group wants to contribute to an improvement of this situation for LMD patients by using an intrathecal application route for the PD1 antibody, i.e. a drug that has shown clinical efficacy in the underlying tumor via the intravenous route.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Universitätsklinikum Bonn, Bonn, , Germany
University Hospital Freiburg, Neurosurgery, Freiburg, , Germany
University Hospital Heidelberg, Neurooncology, Heidelberg, , Germany
SLK-Kliniken Heilbronn GmbH Klinik, Heilbronn, , Germany
University Hospital Mannheim, Neurology Clinic, Mannheim, , Germany
Klinikum rechts der Isar/Technische Universität München, München, , Germany
Katharinenhospital Stuttgart, Stuttgart, , Germany
University Hospital Tübingen, Neurooncology, Tübingen, , Germany
University Hospital Ulm, ECTU - Early Clinical Trail Unit, Ulm, , Germany
Name: Ghazaleh Tabatabai, Prof.Dr.
Affiliation: University Hospital Tuebingen
Role: STUDY_DIRECTOR